{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:05:49Z","timestamp":1790334349515,"version":"4.1.0"},"reference-count":199,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007185","name":"University of California, Los Angeles","doi-asserted-by":"publisher","award":["UCLA MIMG M. John Pickett Post-Doctoral Fellow Award"],"award-info":[{"award-number":["UCLA MIMG M. John Pickett Post-Doctoral Fellow Award"]}],"id":[{"id":"10.13039\/100007185","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Biomed Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor (CAR)-T cells have demonstrated remarkable efficacy in several hematologic malignancies; however, their application in myeloid malignancies such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) remains limited, with no FDA-approved products to date. This limited progress largely reflects both efficacy challenges and safety concerns. CAR-T cells demonstrate poor trafficking and persistence within the bone marrow, limited activity against leukemia stem cells (LSCs), and reliance on antigens such as CD33 and CD123 that are also expressed on normal hematopoietic stem and progenitor cells, resulting in significant on-target off-tumor toxicity. Given these limitations, attention has increasingly shifted toward alternative CAR-engineered immune cells, including CAR-natural killer (CAR-NK) cells, CAR-invariant natural killer T (CAR-NKT) cells, and CAR-macrophages (CAR-Ms). These platforms offer unique advantages, such as intrinsic antitumor activity, distinct trafficking properties, reduced risk of graft-versus-host disease (GvHD), and potentially safer antigen recognition profiles, that may help overcome barriers faced by CAR-T cells. In this review, we highlight the challenges of applying conventional CAR-T cells to myeloid malignancies, examine emerging alternative CAR-cell platforms, and discuss how their unique biology and engineering strategies may provide safer, more effective, and more accessible therapeutic options for patients with these difficult-to-treat cancers.<\/jats:p>","DOI":"10.1186\/s12929-026-01265-8","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T18:04:10Z","timestamp":1780596250000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Exploring CAR cell therapies beyond CAR-T for myeloid malignancies"],"prefix":"10.1186","volume":"33","author":[{"given":"Yan-Ruide","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuning","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"1265_CR1","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1001\/jama.2022.14578","volume":"328","author":"MA Sekeres","year":"2022","unstructured":"Sekeres MA, Taylor J. Diagnosis and treatment of myelodysplastic syndromes: a review. JAMA. 2022;328:872\u201380.","journal-title":"JAMA"},{"key":"1265_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, Jabbour E, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11:41.","journal-title":"Blood Cancer J"},{"key":"1265_CR3","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41586-020-2864-x","volume":"587","author":"LA Miles","year":"2020","unstructured":"Miles LA, Bowman RL, Merlinsky TR, Csete IS, Ooi AT, Durruthy-Durruthy R, et al. Single-cell mutation analysis of clonal evolution in myeloid malignancies. Nature. 2020;587:477\u201382.","journal-title":"Nature"},{"key":"1265_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.50","volume":"6","author":"I De Kouchkovsky","year":"2016","unstructured":"De Kouchkovsky I, Abdul-Hay M. \u201cAcute myeloid leukemia: a comprehensive review and 2016 update.\u201d Blood Cancer J. 2016;6:e441.","journal-title":"Blood Cancer J"},{"key":"1265_CR5","doi-asserted-by":"publisher","first-page":"5722","DOI":"10.3390\/cancers13225722","volume":"13","author":"M Fleischmann","year":"2021","unstructured":"Fleischmann M, Schnetzke U, Hochhaus A, Scholl S. Management of acute myeloid leukemia: current treatment options and future perspectives. Cancers. 2021;13:5722.","journal-title":"Cancers"},{"key":"1265_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-020-00765-5","volume":"21","author":"F Thol","year":"2020","unstructured":"Thol F, Ganser A. Treatment of relapsed acute myeloid leukemia. Curr Treat Options Oncol. 2020;21:66.","journal-title":"Curr Treat Options Oncol"},{"key":"1265_CR7","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1200\/JCO.2010.31.0854","volume":"29","author":"G Garcia-Manero","year":"2011","unstructured":"Garcia-Manero G, Fenaux P. Hypomethylating agents and other novel strategies in myelodysplastic syndromes. J Clin Oncol. 2011;29:516\u201323.","journal-title":"J Clin Oncol"},{"key":"1265_CR8","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/bjh.17746","volume":"196","author":"S Kayser","year":"2022","unstructured":"Kayser S, Levis MJ. Updates on targeted therapies for acute myeloid leukaemia. Br J Haematol. 2022;196:316\u201328.","journal-title":"Br J Haematol"},{"key":"1265_CR9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40164-021-00233-2","volume":"10","author":"Y Yao","year":"2021","unstructured":"Yao Y, Li F, Huang J, Jin J, Wang H. Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development. Exp Hematol Oncol. 2021;10:39. https:\/\/doi.org\/10.1186\/s40164-021-00233-2.","journal-title":"Exp Hematol Oncol"},{"key":"1265_CR10","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s12015-021-10308-6","volume":"18","author":"NA Long","year":"2022","unstructured":"Long NA, Golla U, Sharma A, Claxton DF. Acute myeloid leukemia stem cells: origin, characteristics, and clinical implications. Stem Cell Rev Rep. 2022;18:1211\u201326.","journal-title":"Stem Cell Rev Rep"},{"key":"1265_CR11","doi-asserted-by":"crossref","unstructured":"Maucher M, Srour M, Danhof S, Einsele H, Hudecek M, Yakoub-Agha I. Current limitations and perspectives of chimeric antigen receptor-T-cells in acute myeloid leukemia. Cancers. 2021;13.","DOI":"10.3390\/cancers13246157"},{"key":"1265_CR12","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41568-019-0230-9","volume":"20","author":"D Vetrie","year":"2020","unstructured":"Vetrie D, Helgason GV, Copland M. The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. Nat Rev Cancer. 2020;20:158\u201373.","journal-title":"Nat Rev Cancer"},{"key":"1265_CR13","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/bjh.16354","volume":"188","author":"C Oliai","year":"2020","unstructured":"Oliai C, Schiller G. How to address second and therapy-related acute myelogenous leukaemia. Br J Haematol. 2020;188:116\u201328.","journal-title":"Br J Haematol"},{"key":"1265_CR14","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.15537\/smj.2024.45.10.20240330","volume":"45","author":"A Almotiri","year":"2024","unstructured":"Almotiri A. CAR T-cell therapy in acute myeloid leukemia. Saudi Med J. 2024;45:1007\u201319.","journal-title":"Saudi Med J"},{"key":"1265_CR15","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1182\/blood-2023-179667","volume":"142","author":"NN Shah","year":"2023","unstructured":"Shah NN, Tasian SK, Kohler ME, Hsieh EM, Baumeister SHC, Summers C, et al. CD33 CAR T-Cells (CD33CART) for children and young adults with relapsed\/refractory AML: dose-escalation results from a phase I\/II multicenter trial. Blood. 2023;142:771. https:\/\/doi.org\/10.1182\/blood-2023-179667.","journal-title":"Blood"},{"key":"1265_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100639","volume":"3","author":"J Mirazee","year":"2022","unstructured":"Mirazee J, Shah NN. CD70 CAR T cells in AML: form follows function. Cell Rep Med. 2022;3:100639.","journal-title":"Cell Rep Med"},{"key":"1265_CR17","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1182\/blood.2020008221","volume":"138","author":"T Sauer","year":"2021","unstructured":"Sauer T, Parikh K, Sharma S, Omer B, Sedloev D, Chen Q, et al. CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Blood. 2021;138:318\u201330. https:\/\/doi.org\/10.1182\/blood.2020008221.","journal-title":"Blood"},{"key":"1265_CR18","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/s41467-025-56270-6","volume":"16","author":"Y-R Li","year":"2025","unstructured":"Li Y-R, Fang Y, Niu S, Zhu Y, Chen Y, Lyu Z, et al. Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies. Nat Commun. 2025;16:1248.","journal-title":"Nat Commun"},{"key":"1265_CR19","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1186\/s12967-023-04575-9","volume":"21","author":"Y-R Li","year":"2023","unstructured":"Li Y-R, Fang Y, Lyu Z, Zhu Y, Yang L. Exploring the dynamic interplay between cancer stem cells and the tumor microenvironment: implications for novel therapeutic strategies. J Transl Med. 2023;21:686.","journal-title":"J Transl Med"},{"key":"1265_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12929-024-00998-8","volume":"31","author":"Y-R Li","year":"2024","unstructured":"Li Y-R, Halladay T, Yang L. Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies. J Biomed Sci. 2024;31:5. https:\/\/doi.org\/10.1186\/s12929-024-00998-8.","journal-title":"J Biomed Sci"},{"key":"1265_CR21","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","volume":"173","author":"MY Kim","year":"2018","unstructured":"Kim MY, Yu K-R, Kenderian SS, Ruella M, Chen S, Shin T-H, et al. Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell. 2018;173:1439-1453.e19.","journal-title":"Cell"},{"key":"1265_CR22","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1097\/CJI.0b013e318053ed8e","volume":"30","author":"X Du","year":"2007","unstructured":"Du X, Ho M, Pastan I. New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells. J Immunother. 2007;30:607\u201313.","journal-title":"J Immunother"},{"key":"1265_CR23","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1182\/blood.V130.Suppl_1.1359.1359","volume":"130","author":"KD Cummins","year":"2017","unstructured":"Cummins KD, Frey N, Nelson AM, Schmidt A, Luger S, Isaacs RE, et al. Treating relapsed \/ refractory (RR) AML with biodegradable anti-CD123 CAR modified T Cells. Blood. 2017;130:1359. https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.1359.1359.","journal-title":"Blood"},{"key":"1265_CR24","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. \u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19:185\u201399. https:\/\/doi.org\/10.1038\/s41573-019-0051-2.","journal-title":"Nat Rev Drug Discov"},{"key":"1265_CR25","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41571-021-00485-1","volume":"18","author":"AM DiNofia","year":"2021","unstructured":"DiNofia AM, Grupp SA. Will allogeneic CAR T cells for CD19(+) malignancies take autologous CAR T cells \u201coff the shelf\u201d? Nat Rev Clin Oncol. 2021;18:195\u20136.","journal-title":"Nat Rev Clin Oncol"},{"key":"1265_CR26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41571-024-00959-y","volume":"22","author":"C Diorio","year":"2025","unstructured":"Diorio C, Teachey DT, Grupp SA. Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks. Nat Rev Clin Oncol. 2025;22:10\u201327.","journal-title":"Nat Rev Clin Oncol"},{"key":"1265_CR27","doi-asserted-by":"crossref","unstructured":"Li Y-R, Fang Y, Niu S, Chen Y, Lyu Z, Yang L. Managing allorejection in off-the-shelf CAR-engineered cell therapies. Mol Ther. 2024.","DOI":"10.1016\/j.ymthe.2024.11.035"},{"key":"1265_CR28","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40164-025-00654-3","volume":"14","author":"Z Lyu","year":"2025","unstructured":"Lyu Z, Niu S, Fang Y, Chen Y, Li Y-R, Yang L. Addressing graft-versus-host disease in allogeneic cell-based immunotherapy for cancer. Exp Hematol Oncol. 2025;14:66.","journal-title":"Exp Hematol Oncol"},{"key":"1265_CR29","doi-asserted-by":"crossref","unstructured":"Li Y-R, Zhu Y, Fang Y, Lyu Z, Yang L. Emerging trends in clinical allogeneic CAR cell therapy. Med. 2025;100677.","DOI":"10.1016\/j.medj.2025.100677"},{"key":"1265_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00060","author":"C Zhang","year":"2020","unstructured":"Zhang C, Hu Y, Shi C. Targeting natural killer cells for tumor immunotherapy. Front Immunol. 2020. https:\/\/doi.org\/10.3389\/fimmu.2020.00060.","journal-title":"Front Immunol"},{"key":"1265_CR31","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1016\/j.ymthe.2017.06.012","volume":"25","author":"K Rezvani","year":"2017","unstructured":"Rezvani K, Rouce R, Liu E, Shpall E. Engineering natural killer cells for cancer immunotherapy. Mol Ther. 2017;25:1769\u201381. https:\/\/doi.org\/10.1016\/j.ymthe.2017.06.012.","journal-title":"Mol Ther"},{"key":"1265_CR32","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1182\/blood.2022016201","volume":"141","author":"AN Courtney","year":"2023","unstructured":"Courtney AN, Tian G, Metelitsa LS. Natural killer T cells and other innate-like T lymphocytes as emerging platforms for allogeneic cancer cell therapy. Blood. 2023;141:869\u201376. https:\/\/doi.org\/10.1182\/blood.2022016201.","journal-title":"Blood"},{"key":"1265_CR33","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","volume":"22","author":"TJ Laskowski","year":"2022","unstructured":"Laskowski TJ, Biederst\u00e4dt A, Rezvani K. Natural killer cells in antitumour adoptive cell immunotherapy. Nat Rev Cancer. 2022;22:557\u201375.","journal-title":"Nat Rev Cancer"},{"key":"1265_CR34","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.ccell.2018.08.017","volume":"34","author":"A Rotolo","year":"2018","unstructured":"Rotolo A, Caputo VS, Holubova M, Baxan N, Dubois O, Chaudhry MS, et al. Enhanced anti-lymphoma activity of CAR19-iNKT cells underpinned by dual CD19 and CD1d targeting. Cancer Cell. 2018;34:596-610.e11. https:\/\/doi.org\/10.1016\/j.ccell.2018.08.017.","journal-title":"Cancer Cell"},{"key":"1265_CR35","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.trsl.2017.06.003","volume":"187","author":"D Bollino","year":"2017","unstructured":"Bollino D, Webb TJ. Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy. Transl Res. 2017;187:32\u201343.","journal-title":"Transl Res"},{"key":"1265_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100804","author":"Y-R Li","year":"2025","unstructured":"Li Y-R, Li Z, Zhu Y, Li M, Chen Y, Lee D, et al. Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells. Med. 2025. https:\/\/doi.org\/10.1016\/j.medj.2025.100804.","journal-title":"Med"},{"key":"1265_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.09.026","author":"Y-R Li","year":"2025","unstructured":"Li Y-R, Zhu Y, Li Z, Shen X, Halladay T, Tse C, et al. Allogeneic stem cell-engineered EGFRvIII-specific CAR-NKT cells for treating glioblastoma with enhanced efficacy and safety. Mol Ther. 2025. https:\/\/doi.org\/10.1016\/j.ymthe.2025.09.026.","journal-title":"Mol Ther"},{"key":"1265_CR38","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.36688","author":"MA Morrissey","year":"2018","unstructured":"Morrissey MA, Williamson AP, Steinbach AM, Roberts EW, Kern N, Headley MB, et al. Chimeric antigen receptors that trigger phagocytosis. Elife. 2018. https:\/\/doi.org\/10.7554\/eLife.36688.","journal-title":"Elife"},{"key":"1265_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116925","volume":"177","author":"F Wei","year":"2024","unstructured":"Wei F, Liu H, Wang Y, Li Y, Han S. Engineering macrophages and their derivatives: a new hope for antitumor therapy. Biomed Pharmacother. 2024;177:116925.","journal-title":"Biomed Pharmacother"},{"key":"1265_CR40","doi-asserted-by":"publisher","first-page":"TPS2682","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2682","volume":"42","author":"Y Abdou","year":"2024","unstructured":"Abdou Y, Pohlmann PR, Maziarz RT, Murthy HS, Yuan Y, Krishnamurthy A, et al. A phase 1, first-in-human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2-overexpressing solid tumors. J Clin Oncol. 2024;42:TPS2682\u2013TPS2682. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.TPS2682.","journal-title":"J Clin Oncol"},{"key":"1265_CR41","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020;38:947\u201353.","journal-title":"Nat Biotechnol"},{"key":"1265_CR42","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","volume":"19","author":"N Shimasaki","year":"2020","unstructured":"Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020;19:200\u201318.","journal-title":"Nat Rev Drug Discov"},{"key":"1265_CR43","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nri3174","volume":"12","author":"E Vivier","year":"2012","unstructured":"Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol. 2012;12:239\u201352.","journal-title":"Nat Rev Immunol"},{"key":"1265_CR44","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","volume":"18","author":"JA Myers","year":"2021","unstructured":"Myers JA, Miller JS. Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 2021;18:85\u2013100. https:\/\/doi.org\/10.1038\/s41571-020-0426-7.","journal-title":"Nat Rev Clin Oncol"},{"key":"1265_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.01205","volume":"10","author":"W Hu","year":"2019","unstructured":"Hu W, Wang G, Huang D, Sui M, Xu Y. Cancer immunotherapy based on natural killer cells: current progress and new opportunities. Front Immunol. 2019;10:1\u201316.","journal-title":"Front Immunol"},{"key":"1265_CR46","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1182\/blood.2022016200","volume":"141","author":"MM Berrien-Elliott","year":"2023","unstructured":"Berrien-Elliott MM, Jacobs MT, Fehniger TA. Allogeneic natural killer cell therapy. Blood. 2023;141:856\u201368. https:\/\/doi.org\/10.1182\/blood.2022016200.","journal-title":"Blood"},{"key":"1265_CR47","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41408-022-00660-2","volume":"12","author":"N Albinger","year":"2022","unstructured":"Albinger N, Pfeifer R, Nitsche M, Mertlitz S, Campe J, Stein K, et al. Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia. Blood Cancer J. 2022;12:61.","journal-title":"Blood Cancer J"},{"key":"1265_CR48","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/s41409-023-02180-4","volume":"59","author":"N Albinger","year":"2024","unstructured":"Albinger N, M\u00fcller S, Kostyra J, Kuska J, Mertlitz S, Penack O, et al. Manufacturing of primary CAR-NK cells in an automated system for the treatment of acute myeloid leukemia. Bone Marrow Transplant. 2024;59:489\u201395.","journal-title":"Bone Marrow Transplant"},{"key":"1265_CR49","doi-asserted-by":"publisher","first-page":"8439","DOI":"10.1038\/s41467-024-52388-1","volume":"15","author":"T Bexte","year":"2024","unstructured":"Bexte T, Albinger N, Al Ajami A, Wendel P, Buchinger L, Gessner A, et al. CRISPR\/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells. Nat Commun. 2024;15:8439.","journal-title":"Nat Commun"},{"key":"1265_CR50","doi-asserted-by":"crossref","unstructured":"Christodoulou I, Ho WJ, Marple A, Ravich JW, Tam A, Rahnama R, et al. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities. J Immunother cancer. 2021;9:e003894. https:\/\/pubmed.ncbi.nlm.nih.gov\/34896980.","DOI":"10.1136\/jitc-2021-003894"},{"key":"1265_CR51","doi-asserted-by":"crossref","unstructured":"Tian G, Courtney AN, Yu H, Bhar S, Xu X, Barrag\u00e1n GA, et al. Hyperleukocytosis in a neuroblastoma patient after treatment with natural killer T cells expressing a GD2-specific chimeric antigen receptor and IL-15. J Immunother cancer. 2025;13.","DOI":"10.1136\/jitc-2025-011858"},{"key":"1265_CR52","doi-asserted-by":"crossref","unstructured":"Li Y-R, Zhu Y, Yang L. IL-15 in CAR engineering: striking an efficacy-safety balance. Trends Mol Med. 2025.","DOI":"10.1016\/j.molmed.2025.05.014"},{"key":"1265_CR53","doi-asserted-by":"crossref","unstructured":"Steffin D, Ghatwai N, Montalbano A, Rathi P, Courtney AN, Arnett AB, et al. Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature. 2024.","DOI":"10.1038\/s41586-024-08261-8"},{"key":"1265_CR54","doi-asserted-by":"crossref","unstructured":"Caruso S, De Angelis B, Del Bufalo F, Ciccone R, Donsante S, Volpe G, et al. Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia. J Hematol Oncol. 2022;15:163.","DOI":"10.1186\/s13045-022-01376-3"},{"key":"1265_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216103","volume":"558","author":"R Zhang","year":"2023","unstructured":"Zhang R, Liu Q, Zhou S, He H, Zhao M, Ma W. Engineering CAR-NK cells targeting CD33 with concomitant extracellular secretion of anti-CD16 antibody revealed superior antitumor effects toward myeloid leukemia. Cancer Lett. 2023;558:216103.","journal-title":"Cancer Lett"},{"key":"1265_CR56","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13045-024-01604-y","volume":"17","author":"D Sedloev","year":"2024","unstructured":"Sedloev D, Chen Q, Unglaub JM, Schanda N, Hao Y, Besiridou E, et al. Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia. J Hematol Oncol. 2024;17:85.","journal-title":"J Hematol Oncol"},{"key":"1265_CR57","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1182\/blood-2024-210286","volume":"144","author":"DN Sedloev","year":"2024","unstructured":"Sedloev DN, Chen Q, Unglaub JM, Schmitt A, M\u00fcller-Tidow C, Schmitt M, et al. Structurally optimized, IL-2-armored CLL1 CAR-NK cells are highly potent effectors against AML without Hpsc toxicity. Blood. 2024;144:3440. https:\/\/doi.org\/10.1182\/blood-2024-210286.","journal-title":"Blood"},{"key":"1265_CR58","doi-asserted-by":"crossref","unstructured":"Du Z, Ng YY, Zha S, Wang S. piggyBac system to co-express NKG2D CAR and IL-15 to augment the in\u00a0vivo persistence and anti-AML activity of human peripheral blood NK cells. Mol Ther - Methods Clin Dev. 2021;23:582\u201396.","DOI":"10.1016\/j.omtm.2021.10.014"},{"key":"1265_CR59","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2122379119","volume":"119","author":"H Dong","year":"2022","unstructured":"Dong H, Ham JD, Hu G, Xie G, Vergara J, Liang Y, et al. Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia. Proc Natl Acad Sci. 2022;119:e2122379119.","journal-title":"Proc Natl Acad Sci"},{"key":"1265_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40164-024-00592-6","volume":"14","author":"R Huang","year":"2025","unstructured":"Huang R, Wang X, Yan H, Tan X, Ma Y, Wang M, et al. Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed\/refractory AML: preclinical evaluation and phase I trial. Exp Hematol Oncol. 2025;14:1.","journal-title":"Exp Hematol Oncol"},{"key":"1265_CR61","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.tibtech.2023.02.003","volume":"41","author":"D Xue","year":"2023","unstructured":"Xue D, Lu S, Zhang H, Zhang L, Dai Z, Kaufman DS, et al. Induced pluripotent stem cell-derived engineered T cells, natural killer cells, macrophages, and dendritic cells in immunotherapy. Trends Biotechnol. 2023;41:907\u201322.","journal-title":"Trends Biotechnol"},{"key":"1265_CR62","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","volume":"23","author":"Y Li","year":"2018","unstructured":"Li Y, Hermanson DL, Moriarity BS, Kaufman DS. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell. 2018;23:181-192.e5.","journal-title":"Cell Stem Cell"},{"key":"1265_CR63","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1182\/blood-2021-153484","volume":"138","author":"RM Mbofung","year":"2021","unstructured":"Mbofung RM, Williams AM, Hayama K, Pan Y, Groff B, Dailey T, et al. Off-the-shelf, iPSC-derived CAR-NK cells multiplexed-engineered for the avoidance of allogeneic host immune cell rejection. Blood. 2021;138:2795.","journal-title":"Blood"},{"key":"1265_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2025.102515","volume":"20","author":"Y Fang","year":"2025","unstructured":"Fang Y, Chen Y, Li Y-R. Engineering the next generation of allogeneic CAR cells: iPSCs as a scalable and editable platform. Stem cell reports. 2025;20:102515.","journal-title":"Stem cell reports"},{"key":"1265_CR65","first-page":"60","volume":"12","author":"J Zong","year":"2025","unstructured":"Zong J, Li Y-R. iPSC technology revolutionizes CAR-T cell therapy for cancer treatment. Bioeng. 2025;12:60.","journal-title":"Bioeng"},{"key":"1265_CR66","doi-asserted-by":"publisher","first-page":"12685","DOI":"10.1182\/blood-2022-166420","volume":"140","author":"Y Wang","year":"2022","unstructured":"Wang Y, Wang L, Shao M, He X, Yue Y, Zhou Y, et al. Off-the-Shelf, Multiplexed-Engineered iPSC-Derived CD33 CAR-NK Cells for Treatment of Acute Myeloid Leukemia. Blood. 2022;140:12685.","journal-title":"Blood"},{"key":"1265_CR67","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1182\/blood.2021011532","volume":"139","author":"MM Berrien-Elliott","year":"2022","unstructured":"Berrien-Elliott MM, Becker-Hapak M, Cashen AF, Jacobs M, Wong P, Foster M, et al. Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy. Blood. 2022;139:1177\u201383.","journal-title":"Blood"},{"key":"1265_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.960852","volume":"13","author":"X Wang","year":"2022","unstructured":"Wang X, Xiong H, Ning Z. Implications of NKG2A in immunity and immune-mediated diseases. Front Immunol. 2022;13:960852.","journal-title":"Front Immunol"},{"key":"1265_CR69","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1016\/j.ymthe.2024.06.034","volume":"32","author":"Y Gong","year":"2024","unstructured":"Gong Y, Germeraad WTV, Zhang X, Wu N, Li B, Janssen L, et al. NKG2A genetic deletion promotes human primary NK cell anti-tumor responses better than an anti-NKG2A monoclonal antibody. Mol Ther. 2024;32:2711\u201327.","journal-title":"Mol Ther"},{"key":"1265_CR70","doi-asserted-by":"publisher","first-page":"5868","DOI":"10.1182\/bloodadvances.2020002547","volume":"4","author":"R Basar","year":"2020","unstructured":"Basar R, Daher M, Rezvani K. Next-generation cell therapies: the emerging role of CAR-NK cells. Blood Adv. 2020;4:5868\u201376.","journal-title":"Blood Adv"},{"key":"1265_CR71","doi-asserted-by":"publisher","DOI":"10.4110\/in.2020.20.e14","volume":"20","author":"MH Shin","year":"2020","unstructured":"Shin MH, Kim J, Lim SA, Kim J, Kim S-J, Lee K-M. NK cell-based immunotherapies in cancer. Immune Netw. 2020;20:e14.","journal-title":"Immune Netw"},{"key":"1265_CR72","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J, et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial. Nat Med. 2024;30:772\u201384.","journal-title":"Nat Med"},{"key":"1265_CR73","doi-asserted-by":"publisher","first-page":"1734453","DOI":"10.3389\/fimmu.2025.1734453","volume":"16","author":"MG Kennedy","year":"2025","unstructured":"Kennedy MG, Patterson W, Cox ST, Wynn L, Stock da Cunha C, O\u2019Dwyer M, et al. Umbilical cord blood natural killer cells for adoptive immunotherapy: identifying optimal starting material and processing parameters. Front Immunol. 2025;16:1734453.","journal-title":"Front Immunol"},{"key":"1265_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00091","volume":"7","author":"H Klingemann","year":"2016","unstructured":"Klingemann H, Boissel L, Toneguzzo F. Natural killer cells for immunotherapy - advantages of the NK-92 cell line over blood NK cells. Front Immunol. 2016;7:91.","journal-title":"Front Immunol"},{"key":"1265_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.720501","volume":"11","author":"H Lu","year":"2021","unstructured":"Lu H, Zhao X, Li Z, Hu Y, Wang H. From CAR-T cells to CAR-NK cells: a developing immunotherapy method for hematological malignancies. Front Oncol. 2021;11:720501.","journal-title":"Front Oncol"},{"key":"1265_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153839","author":"M Sabbah","year":"2022","unstructured":"Sabbah M, Jondreville L, Lacan C, Norol F, Vieillard V, Roos-Weil D, et al. CAR-NK cells: a chimeric hope or a promising therapy? Cancers. 2022. https:\/\/doi.org\/10.3390\/cancers14153839.","journal-title":"Cancers"},{"key":"1265_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2023.02.009","author":"Y-R Li","year":"2023","unstructured":"Li Y-R, Dunn ZS, Yu Y, Li M, Wang P, Yang L. Advancing cell-based cancer immunotherapy through stem cell engineering. Cell Stem Cell. 2023. https:\/\/doi.org\/10.1016\/j.stem.2023.02.009.","journal-title":"Cell Stem Cell"},{"key":"1265_CR78","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.3390\/cells10123497","volume":"10","author":"Y-R Li","year":"2021","unstructured":"Li Y-R, Dunn ZS, Zhou Y, Lee D, Yang L. Development of stem cell-derived immune cells for off-the-shelf cancer immunotherapies. Cells. 2021;10:3439.","journal-title":"Cells"},{"key":"1265_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2021.08.004","author":"Y-R Li","year":"2021","unstructured":"Li Y-R, Zhou Y, Kramer A, Yang L. Engineering stem cells for cancer immunotherapy. Trends Cancer. 2021. https:\/\/doi.org\/10.1016\/j.trecan.2021.08.004.","journal-title":"Trends Cancer"},{"key":"1265_CR80","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.70045","volume":"14","author":"J Sun","year":"2025","unstructured":"Sun J, Elliott M, Souza-Fonseca-Guimaraes F. Engineered iPSC-derived natural killer cells: recent innovations in translational innate anti-cancer immunotherapy. Clin Transl Immunol. 2025;14:e70045.","journal-title":"Clin Transl Immunol"},{"key":"1265_CR81","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-025-03558-6","volume":"44","author":"N Romanini","year":"2025","unstructured":"Romanini N, Netsrithong R, Themeli M, Tazzari M. Challenges and opportunities of human iPSC-derived NK as \u201coff-the-shelf\u201d cellular therapies. J Exp Clin Cancer Res. 2025;44:327.","journal-title":"J Exp Clin Cancer Res"},{"key":"1265_CR82","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1016\/j.jcyt.2024.05.022","volume":"26","author":"M Madrid","year":"2024","unstructured":"Madrid M, Lakshmipathy U, Zhang X, Bharti K, Wall DM, Sato Y, et al. Considerations for the development of iPSC-derived cell therapies: a review of key challenges by the JSRM-ISCT iPSC Committee. Cytotherapy. 2024;26:1382\u201399.","journal-title":"Cytotherapy"},{"key":"1265_CR83","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s12272-019-01139-8","volume":"42","author":"EA Bae","year":"2019","unstructured":"Bae EA, Seo H, Kim IK, Jeon I, Kang CY. Roles of NKT cells in cancer immunotherapy. Arch Pharm Res. 2019;42:543\u20138. https:\/\/doi.org\/10.1007\/s12272-019-01139-8.","journal-title":"Arch Pharm Res"},{"key":"1265_CR84","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1146\/annurev.immunol.25.022106.141711","volume":"25","author":"A Bendelac","year":"2007","unstructured":"Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol. 2007;25:297\u2013336.","journal-title":"Annu Rev Immunol"},{"key":"1265_CR85","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s12272-019-01139-8","volume":"42","author":"E-A Bae","year":"2019","unstructured":"Bae E-A, Seo H, Kim I-K, Jeon I, Kang C-Y. Roles of NKT cells in cancer immunotherapy. Arch Pharm Res. 2019;42:543\u20138.","journal-title":"Arch Pharm Res"},{"key":"1265_CR86","doi-asserted-by":"crossref","unstructured":"Li Y-R, Zhou K, Zhu Y, Halladay T, Yang L. Breaking the mold: Unconventional T cells in cancer therapy. Cancer Cell. 2024.","DOI":"10.1016\/j.ccell.2024.11.010"},{"key":"1265_CR87","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.4049\/jimmunol.161.7.3271","volume":"161","author":"N Burdin","year":"1998","unstructured":"Burdin N, Brossay L, Koezuka Y, Smiley ST, Grusby MJ, Gui M, et al. Selective ability of mouse CD1 to present glycolipids: alpha-galactosylceramide specifically stimulates V alpha 14+ NK T lymphocytes. J Immunol. 1998;161:3271\u201381.","journal-title":"J Immunol"},{"key":"1265_CR88","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.4049\/jimmunol.1601399","volume":"198","author":"MV Dhodapkar","year":"2017","unstructured":"Dhodapkar MV, Kumar V. Type II NKT cells and their emerging role in health and disease. J Immunol. 2017;198:1015\u201321.","journal-title":"J Immunol"},{"key":"1265_CR89","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-026-01629-3","author":"Y-R Li","year":"2026","unstructured":"Li Y-R, Nan H, Liu Z, Fang Y, Zhu Y, Lyu Z, et al. Engineering an in vivo charging station for CAR-redirected invariant natural killer T cells to enhance cancer therapy. Nat Biomed Eng. 2026. https:\/\/doi.org\/10.1038\/s41551-026-01629-3.","journal-title":"Nat Biomed Eng"},{"key":"1265_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-026-02602-x","author":"Y-R Li","year":"2026","unstructured":"Li Y-R, Li M, Chen Y, Leng H, Zhu Y, Shen X, et al. Spatiotemporal profiling reveals distinct dynamics and checkpoint regulations of CAR-T and CAR-NKT cells against solid tumors. Signal Transduct Target Ther. 2026. https:\/\/doi.org\/10.1038\/s41392-026-02602-x.","journal-title":"Signal Transduct Target Ther"},{"key":"1265_CR91","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1016\/j.ymthe.2026.02.039","volume":"34","author":"X Shen","year":"2026","unstructured":"Shen X, Li Y-R, Yang L. Igniting CAR-NKT cells with IL-18. Mol Ther. 2026;34:1882\u20133.","journal-title":"Mol Ther"},{"key":"1265_CR92","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41467-023-44310-y","volume":"15","author":"E Landoni","year":"2024","unstructured":"Landoni E, Woodcock MG, Barragan G, Casirati G, Cinella V, Stucchi S, et al. IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity. Nat Commun. 2024;15:89.","journal-title":"Nat Commun"},{"key":"1265_CR93","doi-asserted-by":"publisher","first-page":"e14521","DOI":"10.1200\/JCO.2022.40.16_suppl.e14521","volume":"40","author":"RS Shaik","year":"2025","unstructured":"Shaik RS, Rathi P, Courtney A, Schneller N, Guo L, Barragan G, et al. Glypican-3-specific CAR-NKT cells overexpressing BATF3 mediate potent antitumor activity against hepatocellular carcinoma. J Clin Oncol. 2025;40:e14521\u2013e14521.","journal-title":"J Clin Oncol"},{"key":"1265_CR94","doi-asserted-by":"publisher","first-page":"108597","DOI":"10.1016\/j.isci.2023.108597","volume":"27","author":"Y Liu","year":"2024","unstructured":"Liu Y, Dang Y, Zhang C, Liu L, Cai W, Li L, et al. IL-21-armored B7H3 CAR-iNKT cells exert potent antitumor effects. iScience. 2024;27:108597.","journal-title":"iScience"},{"key":"1265_CR95","doi-asserted-by":"publisher","first-page":"7126","DOI":"10.1158\/1078-0432.CCR-19-0421","volume":"25","author":"X Xu","year":"2019","unstructured":"Xu X, Huang W, Heczey A, Liu D, Guo L, Wood M, et al. NKT cells coexpressing a GD2-specific chimeric antigen receptor and IL15 show enhanced in vivo persistence and antitumor activity against neuroblastoma. Clin Cancer Res. 2019;25:7126\u201338.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1265_CR96","doi-asserted-by":"publisher","first-page":"160721","DOI":"10.1038\/s43018-024-00830-0","volume":"5","author":"X Zhou","year":"2024","unstructured":"Zhou X, Wang Y, Dou Z, Delfanti G, Tsahouridis O, Pellegry CM, et al. CAR-redirected natural killer T cells demonstrate superior antitumor activity to CAR-T cells through multimodal CD1d-dependent mechanisms. Nat cancer. 2024;5(11):160721.","journal-title":"Nat cancer"},{"key":"1265_CR97","doi-asserted-by":"crossref","unstructured":"Li Y-R, Zhou Y, Yu J, Zhu Y, Lee D, Zhu E, et al. Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy. Mol Ther. 2024. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/38584391.","DOI":"10.1016\/j.ymthe.2024.04.005"},{"key":"1265_CR98","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02226-y","author":"Y-R Li","year":"2024","unstructured":"Li Y-R, Zhou Y, Yu J, Kim YJ, Li M, Lee D, et al. Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method. Nat Biotechnol. 2024. https:\/\/doi.org\/10.1038\/s41587-024-02226-y.","journal-title":"Nat Biotechnol"},{"key":"1265_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100449","volume":"2","author":"Y-R Li","year":"2021","unstructured":"Li Y-R, Zhou Y, Kim YJ, Zhu Y, Ma F, Yu J, et al. Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy. Cell Rep Med. 2021;2:100449.","journal-title":"Cell Rep Med"},{"key":"1265_CR100","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/s41591-020-1074-2","volume":"26","author":"A Heczey","year":"2020","unstructured":"Heczey A, Courtney AN, Montalbano A, Robinson S, Liu K, Li M, et al. Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis. Nat Med. 2020;26:1686\u201390. https:\/\/doi.org\/10.1038\/s41591-020-1074-2.","journal-title":"Nat Med"},{"key":"1265_CR101","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02363-y","author":"A Heczey","year":"2023","unstructured":"Heczey A, Xu X, Courtney AN, Tian G, Barragan GA, Guo L, et al. Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nat Med. 2023. https:\/\/doi.org\/10.1038\/s41591-023-02363-y.","journal-title":"Nat Med"},{"key":"1265_CR102","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-024-01077-w","author":"Y-R Li","year":"2025","unstructured":"Li Y-R, Zhou K, Lee D, Zhu Y, Halladay T, Yu J, et al. Generating allogeneic CAR-NKT cells for off-the-shelf cancer immunotherapy with genetically engineered HSP cells and feeder-free differentiation culture. Nat Protoc. 2025. https:\/\/doi.org\/10.1038\/s41596-024-01077-w.","journal-title":"Nat Protoc"},{"key":"1265_CR103","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-026-02930-5","author":"Y-R Li","year":"2026","unstructured":"Li Y-R, Shen X, Chen Y, Zhu Y, Huang J, Oliai C, et al. Synergizing hypomethylating agents with off-the-shelf CD70-targeted chimeric antigen receptor-engineered natural killer T cells for the treatment of acute myeloid leukemia. Leukemia. 2026. https:\/\/doi.org\/10.1038\/s41375-026-02930-5.","journal-title":"Leukemia"},{"key":"1265_CR104","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6074.IO2026-A022","volume":"14","author":"Y-R Li","year":"2026","unstructured":"Li Y-R, Shen X, Chen Y, Yang L. Abstract A022: Synergizing hypomethylating agents with off-the-shelf CD70-targeted CAR-engineered natural killer T cells for the treatment of acute myeloid leukemia. Cancer Immunol Res. 2026;14:A022\u2013A022. https:\/\/doi.org\/10.1158\/2326-6074.IO2026-A022.","journal-title":"Cancer Immunol Res"},{"key":"1265_CR105","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/nri3328","volume":"12","author":"J Rossjohn","year":"2012","unstructured":"Rossjohn J, Pellicci DG, Patel O, Gapin L, Godfrey DI. Recognition of CD1d-restricted antigens by natural killer T cells. Nat Rev Immunol. 2012;12:845\u201357.","journal-title":"Nat Rev Immunol"},{"key":"1265_CR106","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3389\/fimmu.2015.00362","volume":"6","author":"E Macho-Fernandez","year":"2015","unstructured":"Macho-Fernandez E, Brigl M. The extended family of CD1d-restricted NKT cells: sifting through a mixed bag of TCRs, antigens, and functions. Front Immunol. 2015;6:362.","journal-title":"Front Immunol"},{"key":"1265_CR107","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1038\/s41375-024-02351-2","volume":"38","author":"D Atar","year":"2024","unstructured":"Atar D, Ruoff L, Mast A-S, Krost S, Moustafa-Oglou M, Scheuermann S, et al. Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemia. Leukemia. 2024;38:2183\u201395.","journal-title":"Leukemia"},{"key":"1265_CR108","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s40164-024-00549-9","volume":"13","author":"J Li","year":"2024","unstructured":"Li J, Chen P, Ma W. The next frontier in immunotherapy: potential and challenges of CAR-macrophages. Exp Hematol Oncol. 2024;13:76.","journal-title":"Exp Hematol Oncol"},{"key":"1265_CR109","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS2666","volume":"41","author":"Y Abdou","year":"2023","unstructured":"Abdou Y, Dees EC, Mortimer JE, Pohlmann PR, Johnson ML, Maziarz RT, et al. A phase 1, first-in-human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2-overexpressing solid tumors. J Clin Oncol. 2023;41:TPS2666\u2013TPS2666. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.TPS2666.","journal-title":"J Clin Oncol"},{"key":"1265_CR110","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s40364-023-00537-x","volume":"11","author":"K Hadiloo","year":"2023","unstructured":"Hadiloo K, Taremi S, Heidari M, Esmaeilzadeh A. The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors. Biomark Res. 2023;11:103.","journal-title":"Biomark Res"},{"key":"1265_CR111","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55770-1","volume":"16","author":"S Pierini","year":"2025","unstructured":"Pierini S, Gabbasov R, Oliveira-Nunes MC, Qureshi R, Worth A, Huang S, et al. Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models. Nat Commun. 2025;16:706.","journal-title":"Nat Commun"},{"key":"1265_CR112","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.764698","volume":"9","author":"DB Pimenta","year":"2021","unstructured":"Pimenta DB, Varela VA, Datoguia TS, Caraciolo VB, Lopes GH, Pereira WO. The bone marrow microenvironment mechanisms in Acute Myeloid Leukemia. Front Cell Dev Biol. 2021;9:764698.","journal-title":"Front Cell Dev Biol"},{"issue":"10","key":"1265_CR113","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.3390\/biomedicines12102306","volume":"12","author":"O Mesaros","year":"2024","unstructured":"Mesaros O, Onciul M, Matei E, Joldes C, Jimbu L, Neaga A, et al. Macrophages as potential therapeutic targets in acute myeloid leukemia. Biomedicines. 2024;12(10):2306.","journal-title":"Biomedicines"},{"key":"1265_CR114","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1723270","volume":"16","author":"Y-M Yang","year":"2025","unstructured":"Yang Y-M, Ding Y-F, Hu Y-Y, Fan F, Zhao J-L. CAR-M therapy in the era of tumor immunotherapy: current research progress and engineering strategies. Front Immunol. 2025;16:1723270.","journal-title":"Front Immunol"},{"key":"1265_CR115","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00637-2","volume":"12","author":"J Lu","year":"2024","unstructured":"Lu J, Ma Y, Li Q, Xu Y, Xue Y, Xu S. CAR macrophages: a promising novel immunotherapy for solid tumors and beyond. Biomark Res. 2024;12:86.","journal-title":"Biomark Res"},{"key":"1265_CR116","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1464218","volume":"12","author":"T Huang","year":"2024","unstructured":"Huang T, Bei C, Hu Z, Li Y. CAR-macrophage: breaking new ground in cellular immunotherapy. Front Cell Dev Biol. 2024;12:1464218.","journal-title":"Front Cell Dev Biol"},{"key":"1265_CR117","doi-asserted-by":"crossref","unstructured":"Abdin SM, Paasch D, Morgan M, Lachmann N. CARs and beyond: tailoring macrophage-based cell therapeutics to combat solid malignancies. J Immunother cancer. 2021;9.","DOI":"10.1136\/jitc-2021-002741"},{"key":"1265_CR118","doi-asserted-by":"crossref","unstructured":"Li Y-R, Zhu Y, Halladay T, Yang L. In vivo CAR engineering for immunotherapy. Nat Rev Immunol. 2025.","DOI":"10.1038\/s41577-025-01174-1"},{"key":"1265_CR119","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202103258","volume":"33","author":"M Kang","year":"2021","unstructured":"Kang M, Lee SH, Kwon M, Byun J, Kim D, Kim C, et al. Nanocomplex-mediated in vivo programming to Chimeric Antigen Receptor-M1 Macrophages for cancer therapy. Adv Mater. 2021;33:e2103258.","journal-title":"Adv Mater"},{"key":"1265_CR120","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-023-01810-9","volume":"21","author":"L Gao","year":"2023","unstructured":"Gao L, Shi C, Yang Z, Jing W, Han M, Zhang J, et al. Convection-enhanced delivery of nanoencapsulated gene locoregionally yielding ErbB2\/Her2-specific CAR-macrophages for brainstem glioma immunotherapy. J Nanobiotechnology. 2023;21:56.","journal-title":"J Nanobiotechnology"},{"key":"1265_CR121","doi-asserted-by":"publisher","unstructured":"Reiss K, Ueno N, Yuan Y, Johnson M, Claire Dees E, Chao J, et al. 633 A phase 1, first in human (FIH) study of autologous macrophages containing an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumors. J Immunother Cancer . 2022;10. https:\/\/doi.org\/10.1136\/jitc-2022-SITC2022.0633","DOI":"10.1136\/jitc-2022-SITC2022.0633"},{"key":"1265_CR122","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/s41591-025-03495-z","volume":"31","author":"KA Reiss","year":"2025","unstructured":"Reiss KA, Angelos MG, Dees EC, Yuan Y, Ueno NT, Pohlmann PR, et al. CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial. Nat Med. 2025;31:1171\u201382.","journal-title":"Nat Med"},{"key":"1265_CR123","unstructured":"Tang X, Yang L, Li Z, Nalin AP, Dai H, Xu T, et al. First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J Cancer Res. 2018;8:1083\u20139 https:\/\/pubmed.ncbi.nlm.nih.gov\/30034945."},{"key":"1265_CR124","volume":"8","author":"R Qin","year":"2025","unstructured":"Qin R, Liang Y, Zhou F. Advances in the application of patient-derived xenograft models in acute leukemia resistance. Cancer drug Resist. 2025;8:23.","journal-title":"Cancer drug Resist"},{"key":"1265_CR125","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/s10238-022-00884-3","volume":"23","author":"J Li","year":"2023","unstructured":"Li J, Chen H, Zhao S, Wen D, Bi L. Patient-derived intrafemoral orthotopic xenografts of peripheral blood or bone marrow from Acute Myeloid and Acute Lymphoblastic Leukemia patients: clinical characterization, methodology, and validation. Clin Exp Med. 2023;23:1293\u2013306.","journal-title":"Clin Exp Med"},{"key":"1265_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2025.101520","volume":"12","author":"M Liu","year":"2025","unstructured":"Liu M, Yang X. Patient-derived xenograft models: current status, challenges, and innovations in cancer research. Genes Dis. 2025;12:101520.","journal-title":"Genes Dis"},{"key":"1265_CR127","doi-asserted-by":"publisher","first-page":"100030","DOI":"10.1016\/j.bict.2025.100030","volume":"2","author":"M Drayton","year":"2026","unstructured":"Drayton M, Kuchenbauer F, Cherniawsky H. CAR-NK cell therapy in acute myeloid leukemia: safer, smarter, and moving toward clinical translation. Blood Immunol Cell Ther. 2026;2:100030.","journal-title":"Blood Immunol Cell Ther"},{"key":"1265_CR128","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/s42003-025-09433-6","volume":"9","author":"M Giannini","year":"2026","unstructured":"Giannini M, Campione G, Torcq L, Donadelli S, Bencheikh M, Bounaud S, et al. A human pathophysiological 3D-bone marrow model reveals immune and stromal cell heterogeneity. Commun Biol. 2026;9:164.","journal-title":"Commun Biol"},{"key":"1265_CR129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2018.00283","volume":"9","author":"RS Mehta","year":"2018","unstructured":"Mehta RS, Rezvani K. Chimeric antigen receptor expressing natural killer cells for the immunotherapy of cancer. Front Immunol. 2018;9:1\u201312.","journal-title":"Front Immunol"},{"key":"1265_CR130","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2017.226","volume":"32","author":"E Liu","year":"2018","unstructured":"Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2018;32:520\u201331. https:\/\/doi.org\/10.1038\/leu.2017.226.","journal-title":"Leukemia"},{"key":"1265_CR131","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101889","volume":"6","author":"L Wang","year":"2025","unstructured":"Wang L, Wang Y, He X, Mo Z, Zhao M, Liang X, et al. CD70-targeted iPSC-derived CAR-NK cells display potent function against tumors and alloreactive T cells. Cell reports Med. 2025;6:101889.","journal-title":"Cell reports Med"},{"key":"1265_CR132","doi-asserted-by":"crossref","unstructured":"Dai Z, Zhu Z, Li Z, Tian L, Teng K-Y, Chen H, et al. Off-the-shelf invariant NKT cells expressing anti-PSCA CAR and IL-15 promote pancreatic cancer regression in mice. J Clin Invest. 2025;135(8).","DOI":"10.1172\/JCI179014"},{"key":"1265_CR133","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1182\/blood-2021-149712","volume":"138","author":"CA Ramos","year":"2021","unstructured":"Ramos CA, Courtney AN, Robinson SN, Dakhova O, Lulla PD, Kamble R, et al. Allogeneic NKT cells expressing a CD19-specific CAR in patients with relapsed or refractory B-cell malignancies: an interim analysis. Blood. 2021;138:2819. https:\/\/doi.org\/10.1182\/blood-2021-149712.","journal-title":"Blood"},{"key":"1265_CR134","doi-asserted-by":"publisher","first-page":"104859","DOI":"10.1016\/j.isci.2022.104859","volume":"25","author":"Y-R Li","year":"2022","unstructured":"Li Y-R, Zeng S, Dunn ZS, Zhou Y, Li Z, Yu J, et al. Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers. IScience. 2022;25:104859.","journal-title":"IScience"},{"key":"1265_CR135","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/978-1-0716-1775-5_4","volume":"2388","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Li Y-R, Zeng S, Yang L. Methods for studying mouse and human invariant natural killer T Cells. Methods Mol Biol. 2021;2388:35\u201357.","journal-title":"Methods Mol Biol"},{"key":"1265_CR136","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.stem.2019.08.004","volume":"25","author":"Y Zhu","year":"2019","unstructured":"Zhu Y, Smith DJ, Zhou Y, Li YR, Yu J, Lee D, et al. Development of hematopoietic stem cell-engineered invariant natural killer T cell therapy for cancer. Cell Stem Cell. 2019;25:542\u201357. https:\/\/doi.org\/10.1016\/j.stem.2019.08.004.","journal-title":"Cell Stem Cell"},{"key":"1265_CR137","doi-asserted-by":"crossref","unstructured":"Li Y-R, Zhu Y, Yang L. IL-18 revives dysfunctional CAR-T cells. Trends in cancer. 2025.","DOI":"10.1016\/j.trecan.2025.06.008"},{"key":"1265_CR138","doi-asserted-by":"crossref","unstructured":"Li S, Li Y-R, Nan H, Liu Z, Fang Y, Zhu Y, et al. Engineering an in vivo charging station for CAR-redirected invariant natural killer T cells to enhance cancer therapy. Res Sq. 2025;","DOI":"10.21203\/rs.3.rs-6215345\/v1"},{"key":"1265_CR139","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2025.103957","volume":"6","author":"Z Lyu","year":"2025","unstructured":"Lyu Z, Li Y-R, Yang L. Protocol for assessing pharmacokinetics and pharmacodynamics of human CAR-NKT cells in humanized mouse models using bioluminescence imaging. STAR Protoc. 2025;6:103957.","journal-title":"STAR Protoc"},{"key":"1265_CR140","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.999549","volume":"13","author":"Y-R Li","year":"2022","unstructured":"Li Y-R, Wilson M, Yang L. Target tumor microenvironment by innate T cells. Front Immunol. 2022;13:999549.","journal-title":"Front Immunol"},{"key":"1265_CR141","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1186\/s12967-023-04479-8","volume":"21","author":"Y Chen","year":"2023","unstructured":"Chen Y, Zhu X, Liu H, Wang C, Chen Y, Wang H, et al. The application of HER2 and CD47 CAR-macrophage in ovarian cancer. J Transl Med. 2023;21:654.","journal-title":"J Transl Med"},{"key":"1265_CR142","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1182\/blood-2021-146609","volume":"138","author":"I Christodoulou","year":"2021","unstructured":"Christodoulou I, Koldobskiy M, Ho WJ, Marple A, Ravich WJ, Rahnama R, et al. Engineered interleukin-15 autocrine signaling invigorates anti-CD123 CAR-NK cells. Blood. 2021;138:2806. https:\/\/doi.org\/10.1182\/blood-2021-146609.","journal-title":"Blood"},{"key":"1265_CR143","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1658580","volume":"16","author":"X Xu","year":"2025","unstructured":"Xu X, Cao P, Wang M, Wan Y, Sun S, Chen Y, et al. Signaling intact membrane-bound IL-15 enables potent anti-tumor activity and safety of CAR-NK cells. Front Immunol. 2025;16:1658580.","journal-title":"Front Immunol"},{"key":"1265_CR144","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1146\/annurev-med-073118-011031","volume":"72","author":"WW Overwijk","year":"2021","unstructured":"Overwijk WW, Tagliaferri MA, Zalevsky J. Engineering IL-2 to give new life to T cell immunotherapy. Annu Rev Med. 2021;72:281\u2013311.","journal-title":"Annu Rev Med"},{"key":"1265_CR145","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104539","volume":"90","author":"ME Raeber","year":"2023","unstructured":"Raeber ME, Sahin D, Karakus U, Boyman O. A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases. EBioMedicine. 2023;90:104539.","journal-title":"EBioMedicine"},{"key":"1265_CR146","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1433989","volume":"15","author":"S Rokade","year":"2024","unstructured":"Rokade S, Damani AM, Oft M, Emmerich J. IL-2 based cancer immunotherapies: an evolving paradigm. Front Immunol. 2024;15:1433989.","journal-title":"Front Immunol"},{"key":"1265_CR147","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.884648","volume":"13","author":"I Terr\u00e9n","year":"2022","unstructured":"Terr\u00e9n I, Orrantia A, Astarloa-Pando G, Amarilla-Irusta A, Zenarruzabeitia O, Borrego F. Cytokine-induced memory-like NK cells: from the basics to clinical applications. Front Immunol. 2022;13:884648.","journal-title":"Front Immunol"},{"issue":"357","key":"1265_CR148","doi-asserted-by":"publisher","first-page":"357ra123","DOI":"10.1126\/scitranslmed.aaf2341","volume":"8","author":"R Romee","year":"2016","unstructured":"Romee R, Rosario M, Berrien-Elliott MM, Wagner JA, Jewell BA, Schappe T, et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med. 2016;8(357):357ra123.","journal-title":"Sci Transl Med"},{"key":"1265_CR149","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","volume":"365","author":"A Di Stasi","year":"2011","unstructured":"Di Stasi A, Tey S-K, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365:1673\u201383.","journal-title":"N Engl J Med"},{"key":"1265_CR150","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2014.00235","volume":"5","author":"T Gargett","year":"2014","unstructured":"Gargett T, Brown MP. The inducible caspase-9 suicide gene system as a \u201csafety switch\u201d to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front Pharmacol. 2014;5:235.","journal-title":"Front Pharmacol"},{"key":"1265_CR151","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.ymthe.2017.01.011","volume":"25","author":"I Diaconu","year":"2017","unstructured":"Diaconu I, Ballard B, Zhang M, Chen Y, West J, Dotti G, et al. Inducible caspase-9 selectively modulates the toxicities of CD19-specific chimeric antigen receptor-modified T Cells. Mol Ther. 2017;25:580\u201392.","journal-title":"Mol Ther"},{"key":"1265_CR152","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27196","volume":"10","author":"J Li","year":"2024","unstructured":"Li J, Hu H, Lian K, Zhang D, Hu P, He Z, et al. CAR-NK cells in combination therapy against cancer: a potential paradigm. Heliyon. 2024;10:e27196.","journal-title":"Heliyon"},{"key":"1265_CR153","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1158\/2159-8290.CD-21-1683","volume":"12","author":"RM Young","year":"2022","unstructured":"Young RM, Engel NW, Uslu U, Wellhausen N, June CH. Next-generation CAR T-cell therapies. Cancer Discov. 2022;12:1625\u201333.","journal-title":"Cancer Discov"},{"key":"1265_CR154","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.813832","volume":"12","author":"VM Qin","year":"2021","unstructured":"Qin VM, Haynes NM, D\u2019Souza C, Neeson PJ, Zhu JJ. CAR-T plus radiotherapy: a promising combination for immunosuppressive tumors. Front Immunol. 2021;12:813832.","journal-title":"Front Immunol"},{"key":"1265_CR155","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00535-1","volume":"13","author":"A Van der Vreken","year":"2024","unstructured":"Van der Vreken A, Vanderkerken K, De Bruyne E, De Veirman K, Breckpot K, Menu E. Fueling CARs: metabolic strategies to enhance CAR T-cell therapy. Exp Hematol Oncol. 2024;13:66.","journal-title":"Exp Hematol Oncol"},{"key":"1265_CR156","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100695","volume":"45","author":"R Bansal","year":"2021","unstructured":"Bansal R, Reshef R. Revving the CAR - combination strategies to enhance CAR T cell effectiveness. Blood Rev. 2021;45:100695.","journal-title":"Blood Rev"},{"key":"1265_CR157","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.tips.2024.12.004","volume":"46","author":"Y-R Li","year":"2025","unstructured":"Li Y-R, Lyu Z, Shen X, Fang Y, Yang L. Boosting CAR-T cell therapy through vaccine synergy. Trends Pharmacol Sci. 2025;46:180\u201399.","journal-title":"Trends Pharmacol Sci"},{"issue":"14","key":"1265_CR158","doi-asserted-by":"publisher","first-page":"7547","DOI":"10.3390\/ijms23147547","volume":"23","author":"Y-R Li","year":"2022","unstructured":"Li Y-R, Zhou Y, Wilson M, Kramer A, Hon R, Zhu Y, et al. Tumor-localized administration of \u03b1-GalCer to recruit invariant natural killer T cells and enhance their antitumor activity against solid tumors. Int J Mol Sci. 2022;23(14):7547.","journal-title":"Int J Mol Sci"},{"key":"1265_CR159","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1182\/blood-2021-152692","volume":"138","author":"DA Sallman","year":"2021","unstructured":"Sallman DA, Elmariah H, Sweet K, Talati C, Mishra A, Cox CA, et al. Phase 1\/1b safety study of prgn-3006 Ultracar-T in patients with relapsed or refractory CD33-positive acute myeloid leukemia and higher risk myelodysplastic syndromes. Blood. 2021;138:825.","journal-title":"Blood"},{"key":"1265_CR160","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/s41591-020-0910-8","volume":"26","author":"C Riether","year":"2020","unstructured":"Riether C, Pabst T, H\u00f6pner S, Bacher U, Hinterbrandner M, Banz Y, et al. Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Nat Med. 2020;26:1459\u201367.","journal-title":"Nat Med"},{"key":"1265_CR161","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1053\/j.seminhematol.2018.08.008","volume":"56","author":"KD Cummins","year":"2019","unstructured":"Cummins KD, Gill S. Will CAR T cell therapy have a role in AML? Promises and pitfalls. Semin Hematol. 2019;56:155\u201363.","journal-title":"Semin Hematol"},{"key":"1265_CR162","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.3390\/cancers13112816","volume":"13","author":"IM Michelozzi","year":"2021","unstructured":"Michelozzi IM, Kirtsios E, Giustacchini A. Driving CAR T stem cell targeting in acute myeloid leukemia: the roads to success. Cancers. 2021;13:2816.","journal-title":"Cancers"},{"key":"1265_CR163","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1158\/2643-3230.BCD-23-0258","volume":"6","author":"S Jambon","year":"2025","unstructured":"Jambon S, Sun J, Barman S, Muthugounder S, Bito XR, Shadfar A, et al. CD33-CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T Cells. Blood cancer Discov. 2025;6:55\u201372.","journal-title":"Blood cancer Discov"},{"key":"1265_CR164","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0726-5","volume":"12","author":"H Ma","year":"2019","unstructured":"Ma H, Padmanabhan IS, Parmar S, Gong Y. Targeting CLL-1 for acute myeloid leukemia therapy. J Hematol Oncol. 2019;12:41.","journal-title":"J Hematol Oncol"},{"key":"1265_CR165","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40364-025-00738-6","volume":"13","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H, Zehtabcheh S, Seraji HR, Beqaj SH, Tayefeh S, Mohammadi MH, et al. Unveiling the potential of CLL-1: a promising target for AML therapy. Biomark Res. 2025;13:28.","journal-title":"Biomark Res"},{"key":"1265_CR166","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","volume":"123","author":"S Gill","year":"2014","unstructured":"Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL, et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood. 2014;123:2343\u201354.","journal-title":"Blood"},{"key":"1265_CR167","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-026-06742-6","volume":"105","author":"X Zhao","year":"2026","unstructured":"Zhao X, Ming X, Wu J, Zhu X, Xiao Y. Next-generation CAR-T therapy for acute myeloid leukemia: bridging innovation with clinical translation. Ann Hematol. 2026;105:20.","journal-title":"Ann Hematol"},{"key":"1265_CR168","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-025-00726-4","volume":"14","author":"\u00c1 Oca\u00f1a-Cara","year":"2025","unstructured":"Oca\u00f1a-Cara \u00c1, Mutis T, van der Schans JJ. Emerging strategies in CAR-T cell therapy for acute myeloid leukemia: overcoming heterogeneity and improving safety through dual-antigen targeting. Exp Hematol Oncol. 2025;14:135.","journal-title":"Exp Hematol Oncol"},{"key":"1265_CR169","doi-asserted-by":"publisher","first-page":"6242","DOI":"10.4049\/jimmunol.178.10.6242","volume":"178","author":"AB Pillai","year":"2007","unstructured":"Pillai AB, George TI, Dutt S, Teo P, Strober S. Host NKT cells can prevent Graft-versus-Host Disease and permit graft antitumor activity after bone marrow transplantation. J Immunol. 2007;178:6242\u201351.","journal-title":"J Immunol"},{"key":"1265_CR170","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41577-019-0200-1","volume":"19","author":"R Lanza","year":"2019","unstructured":"Lanza R, Russell DW, Nagy A. Engineering universal cells that evade immune detection. Nat Rev Immunol. 2019;19:723\u201333. https:\/\/doi.org\/10.1038\/s41577-019-0200-1.","journal-title":"Nat Rev Immunol"},{"key":"1265_CR171","doi-asserted-by":"publisher","first-page":"4084","DOI":"10.3390\/ijms24044084","volume":"24","author":"Y Fang","year":"2023","unstructured":"Fang Y, Zhu Y, Kramer A, Chen Y, Li Y-R, Yang L. Graft-versus-host disease modulation by innate T Cells. Int J Mol Sci. 2023;24:4084.","journal-title":"Int J Mol Sci"},{"key":"1265_CR172","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem J, Mansilla-Soto J, Giavridis T, Van Der Stegen SJC, Hamieh M, Cunanan KM, et al. Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature. 2017;543:113\u20137. https:\/\/doi.org\/10.1038\/nature21405.","journal-title":"Nature"},{"key":"1265_CR173","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37785-2","volume":"14","author":"X Hu","year":"2023","unstructured":"Hu X, Manner K, DeJesus R, White K, Gattis C, Ngo P, et al. Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice. Nat Commun. 2023;14:2020. https:\/\/doi.org\/10.1038\/s41467-023-37785-2.","journal-title":"Nat Commun"},{"key":"1265_CR174","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1182\/blood.2020005185","volume":"136","author":"D Stenger","year":"2020","unstructured":"Stenger D, Stief TA, Kaeuferle T, Willier S, Rataj F, Schober K, et al. Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR\/Cas9-mediated TCR knockout CAR. Blood. 2020;136:1407\u201318. https:\/\/doi.org\/10.1182\/blood.2020005185.","journal-title":"Blood"},{"key":"1265_CR175","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-210234","volume":"144","author":"D Chin","year":"2024","unstructured":"Chin D, Lebid A, Idank K, Mendonca M, Perez A, Alexander N, et al. Natural killer and gamma delta T cells derived from engineered induced pluripotent stem cells have potent preclinical activity to treat B cell-mediated autoimmune diseases. Blood. 2024;144:3437. https:\/\/doi.org\/10.1182\/blood-2024-210234.","journal-title":"Blood"},{"key":"1265_CR176","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148654","volume":"138","author":"F Cichocki","year":"2021","unstructured":"Cichocki F, Goodridge JP, Bjordahl R, Gaidarova S, Mahmood S, Abujarour R, et al. Off-the-shelf, multiplexed-engineered iPSC-derived NK cells mediate potent multi-antigen targeting of B-cell malignancies with reduced cytotoxicity against healthy B cells. Blood. 2021;138:407. https:\/\/doi.org\/10.1182\/blood-2021-148654.","journal-title":"Blood"},{"key":"1265_CR177","doi-asserted-by":"crossref","unstructured":"Wang X, Zhang Y, Jin Y, Dai L, Yue Y, Hu J, et al. An iPSC-derived CD19\/BCMA CAR-NK therapy in a patient with systemic sclerosis. Cell. 2025.","DOI":"10.1016\/j.cell.2025.05.038"},{"key":"1265_CR178","doi-asserted-by":"publisher","first-page":"10441","DOI":"10.1073\/pnas.1902566116","volume":"116","author":"X Han","year":"2019","unstructured":"Han X, Wang M, Duan S, Franco PJ, Kenty JH-R, Hedrick P, et al. Generation of hypoimmunogenic human pluripotent stem cells. Proc Natl Acad Sci. 2019;116:10441\u20136.","journal-title":"Proc Natl Acad Sci"},{"key":"1265_CR179","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nbt.3860","volume":"35","author":"GG Gornalusse","year":"2017","unstructured":"Gornalusse GG, Hirata RK, Funk SE, Riolobos L, Lopes VS, Manske G, et al. HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells. Nat Biotechnol. 2017;35:765\u201372.","journal-title":"Nat Biotechnol"},{"key":"1265_CR180","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54129-w","volume":"15","author":"TA Martins","year":"2024","unstructured":"Martins TA, Kaymak D, Tatari N, Gerster F, Hogan S, Ritz M-F, et al. Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRP\u03b3-derived CD47 blocker. Nat Commun. 2024;15:9718.","journal-title":"Nat Commun"},{"key":"1265_CR181","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41586-024-07443-8","volume":"630","author":"SA Yamada-Hunter","year":"2024","unstructured":"Yamada-Hunter SA, Theruvath J, McIntosh BJ, Freitas KA, Lin F, Radosevich MT, et al. Engineered CD47 protects T cells for enhanced antitumour immunity. Nature. 2024;630:457\u201365.","journal-title":"Nature"},{"key":"1265_CR182","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.stem.2015.03.011","volume":"16","author":"M Themeli","year":"2015","unstructured":"Themeli M, Rivi\u00e8re I, Sadelain M. New cell sources for T cell engineering and adoptive immunotherapy. Cell Stem Cell. 2015;16:357\u201366.","journal-title":"Cell Stem Cell"},{"key":"1265_CR183","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00983-2","author":"L Zhang","year":"2020","unstructured":"Zhang L, Tian L, Dai X, Yu H, Wang J, Lei A, et al. Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions. J Hematol Oncol. 2020. https:\/\/doi.org\/10.1186\/s13045-020-00983-2.","journal-title":"J Hematol Oncol"},{"key":"1265_CR184","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-024-02077-1","volume":"10","author":"Y Zhong","year":"2024","unstructured":"Zhong Y, Liu J. Emerging roles of CAR-NK cell therapies in tumor immunotherapy: current status and future directions. Cell Death Discov. 2024;10:318. https:\/\/doi.org\/10.1038\/s41420-024-02077-1.","journal-title":"Cell Death Discov"},{"key":"1265_CR185","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.tips.2020.11.004","volume":"42","author":"D Cort\u00e9s-Selva","year":"2021","unstructured":"Cort\u00e9s-Selva D, Dasgupta B, Singh S, Grewal IS. Innate and innate-like cells: the future of chimeric antigen receptor (CAR) cell therapy. Trends Pharmacol Sci. 2021;42:45\u201359.","journal-title":"Trends Pharmacol Sci"},{"key":"1265_CR186","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1182\/blood-2018-99-110579","volume":"132","author":"F Liu","year":"2018","unstructured":"Liu F, Cao Y, Pinz K, Ma Y, Wada M, Chen K, et al. First-in-human CLL1-CD33 compound CAR T cell therapy induces complete remission in patients with refractory acute myeloid leukemia: update on phase 1 clinical trial. Blood. 2018;132:901.","journal-title":"Blood"},{"key":"1265_CR187","doi-asserted-by":"publisher","first-page":"101805","DOI":"10.1016\/j.nantod.2023.101805","volume":"49","author":"Y Liu","year":"2023","unstructured":"Liu Y, Jing W, Zhang J, Chen C, Gao L, Shi C, et al. In situ MUC1-specific CAR engineering of tumor-supportive macrophages stimulates tumoricidal immunity against pancreatic adenocarcinoma. Nano Today. 2023;49:101805.","journal-title":"Nano Today"},{"key":"1265_CR188","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.jconrel.2023.07.021","volume":"360","author":"Z Yang","year":"2023","unstructured":"Yang Z, Liu Y, Zhao K, Jing W, Gao L, Dong X, et al. Dual mRNA co-delivery for in situ generation of phagocytosis-enhanced CAR macrophages augments hepatocellular carcinoma immunotherapy. J Control Release. 2023;360:718\u201333.","journal-title":"J Control Release"},{"key":"1265_CR189","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn1128","volume":"14","author":"C Chen","year":"2022","unstructured":"Chen C, Jing W, Chen Y, Wang G, Abdalla M, Gao L, et al. Intracavity generation of glioma stem cell-specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy. Sci Transl Med. 2022;14:eabn1128.","journal-title":"Sci Transl Med"},{"key":"1265_CR190","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.tips.2024.03.004","volume":"45","author":"L Short","year":"2024","unstructured":"Short L, Holt RA, Cullis PR, Evgin L. Direct in vivo CAR T cell engineering. Trends Pharmacol Sci. 2024;45:406\u201318.","journal-title":"Trends Pharmacol Sci"},{"key":"1265_CR191","first-page":"266","volume":"23","author":"KP Fabian","year":"2021","unstructured":"Fabian KP, Hodge JW. The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy. Mol Ther. 2021;23:266\u201376.","journal-title":"Mol Ther"},{"key":"1265_CR192","doi-asserted-by":"crossref","unstructured":"Li Y-R, Chen Y, Yang L. Stealth designs to overcome allorejection in engineered cell therapy. Trends Immunol. 2026.","DOI":"10.1016\/j.it.2026.02.008"},{"issue":"1","key":"1265_CR193","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.tips.2025.11.001","volume":"47","author":"Y-R Li","year":"2025","unstructured":"Li Y-R, Yang L. Autologous, allogeneic, in vivo CAR for autoimmune diseases. Trends Pharmacol Sci. 2025;47(1):11\u20134.","journal-title":"Trends Pharmacol Sci"},{"key":"1265_CR194","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/sctm.20-0242","volume":"10","author":"BS Jha","year":"2021","unstructured":"Jha BS, Farnoodian M, Bharti K. Regulatory considerations for developing a phase I investigational new drug application for autologous induced pluripotent stem cells-based therapy product. Stem Cells Transl Med. 2021;10:198\u2013208.","journal-title":"Stem Cells Transl Med"},{"key":"1265_CR195","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102337","volume":"6","author":"Y-R Li","year":"2025","unstructured":"Li Y-R, Yang L. From bench to body: in vivo CAR engineering in the clinic. Cell reports Med. 2025;6:102337.","journal-title":"Cell reports Med"},{"key":"1265_CR196","doi-asserted-by":"crossref","unstructured":"Li Y-R, Zhu Y, Yang L. Clinical technology advances driving in vivo CAR therapy. Trends Biotechnol. 2025.","DOI":"10.1016\/j.tibtech.2025.11.006"},{"key":"1265_CR197","doi-asserted-by":"publisher","first-page":"1384039","DOI":"10.3389\/fimmu.2024.1384039","volume":"15","author":"JC Kong","year":"2024","unstructured":"Kong JC, Sa\u2019ad MA, Vijayan HM, Ravichandran M, Balakrishnan V, Tham SK, et al. Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challenges. Front Immunol. 2024;15:1384039.","journal-title":"Front Immunol"},{"key":"1265_CR198","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1603757","volume":"16","author":"FD Dos Reis","year":"2025","unstructured":"Dos Reis FD, Saidani Y, Mart\u00edn-Rubio P, Sanz-Pamplona R, Stojanovic A, Correia MP. CAR-NK cells: harnessing the power of natural killers for advanced cancer therapy. Front Immunol. 2025;16:1603757.","journal-title":"Front Immunol"},{"key":"1265_CR199","doi-asserted-by":"publisher","unstructured":"Chen Y, Zhu Y, Li Y-R. The Role of Innate T Cells in Cancer BT - Handbook of Cancer and Immunology. In: Rezaei N, editor. Cham: Springer International Publishing. 2022. p. 1\u201318. https:\/\/doi.org\/10.1007\/978-3-030-80962-1_365-1","DOI":"10.1007\/978-3-030-80962-1_365-1"}],"container-title":["Journal of Biomedical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-026-01265-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12929-026-01265-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-026-01265-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T19:02:28Z","timestamp":1780599748000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12929-026-01265-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":199,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1265"],"URL":"https:\/\/doi.org\/10.1186\/s12929-026-01265-8","relation":{},"ISSN":["1423-0127"],"issn-type":[{"value":"1423-0127","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"8 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}